

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT4457375

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
SPINIFEX PHARMACEUTICALS PTY LTD	11/02/2015
RECEIVING PARTY DATA	
Name:	NOVARTIS AG
Street Address:	LICHTSTRASSE 35
City:	BASEL
State/Country:	SWITZERLAND
Postal Code:	4056
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	15149641
CORRESPONDENCE DATA	
Fax Number:	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	6178717506
Email:	safiya.watson@novartis.com
Correspondent Name:	SAFIYA WATSON
Address Line 1:	700 MAIN STREET
Address Line 2:	4TH FLOOR
Address Line 4:	CAMBRIDGE, MASSACHUSETTS 02139
ATTORNEY DOCKET NUMBER:	PAT057022-US-CNT
NAME OF SUBMITTER:	SAFIYA WATSON
SIGNATURE:	/Safiya Watson/
DATE SIGNED:	06/13/2017
Total Attachments: 5	
source=PAT057022_Spinifex assignment to NAG_US_with exhibit#page1.tif	
source=PAT057022_Spinifex assignment to NAG_US_with exhibit#page2.tif	
source=PAT057022_Spinifex assignment to NAG_US_with exhibit#page3.tif	
source=PAT057022_Spinifex assignment to NAG_US_with exhibit#page4.tif	
source=PAT057022_Spinifex assignment to NAG_US_with exhibit#page5.tif	

ASSIGNMENT

This Assignment Agreement is entered into by and between SPINIFEX PHARMACEUTICALS PTY LTD, Corporate One, Suite G5, 84 Hotham Street, Preston, Victoria 3072, Australia, a company organized under the laws of Australia and NOVARTIS AG, a company incorporated in Switzerland whose address is Lichtstrasse 35, 4056 Basel, Switzerland.

For good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, SPINIFEX PHARMACEUTICALS PTY LTD does hereby sell, assign and transfer to NOVARTIS AG and its successors, assigns and legal representatives (hereinafter referred to collectively as the "ASSIGNEE"), all of its right, title and interest for all countries of the world in and to

(1) all inventions and discoveries described in the provisional or non-provisional patent application(s) entitled:

SEE ATTACHED SCHEDULE OF APPLICATIONS (SCHEDULE A)

(2) the application(s) identified in paragraph (1), and all applications claiming priority from such application(s), directly or indirectly, including all national stages of any international patent application(s);

(3) the right to file patent, utility model, or other applications on any invention or discovery disclosed in any of the applications identified in paragraphs (1) and (2), including the right to file such applications on said inventions and discoveries in the names of ASSIGNEE or their designees, or on behalf or in the name(s) of the inventor(s) of said inventions and discoveries, at ASSIGNEE's election and in accordance with applicable law in all countries and regions; and the right to file all patent, utility model, or other applications in all countries and regions claiming the priority of any of the provisional or non-provisional application(s) identified in paragraphs (1) or (2);

(4) all rights to claim priority from any of the applications referred to in paragraphs (1), (2), and (3) or from any application from which any of the applications referred to in paragraphs (1), (2) and (3) claim priority in all countries and regions under the Paris Convention for the Protection of Industrial Property, the WTO GATT TRIPS Agreement, the Inter-American Convention relating to Inventions, Patents, Designs, and Industrial Models and all other international agreements to which the United States now is or hereafter becomes a signatory and, if the United States patent application is a provisional patent application, under 35 USC 119(e);

(5) all continuations, continuations-in-part, and divisionals of any United States patent application(s) or international patent application(s) designating the United States, any national

stages of any international application(s), and any other patent application(s) described in paragraphs (1) through (4) hereof, including further continuations, continuations-in-part, and divisionals such as, but not limited to, continuations of continuations and continuations of divisionals;

(6) all patents, utility models, or other grants that issue from any of the applications referred to herein and all rights and remedies associated therewith including the right to sue for and recover past damages and to recover under 35 U.S.C. § 154 (d) or any other law permitting remedies for infringement prior to issuance of the patent;

(7) all registrations and confirmations of, and importation certificates based upon, one or more of said patents, utility models, or other grants, and applications for such registrations, confirmations and importation certificates and;

(8) all reissues, renewals and extensions of said patents, utility models, registrations, confirmations and importation certificates, reexamination certificates issued for said patents and supplementary protection certificates based upon said patents and applications for such reissues, renewals, extensions, reexamination certificates and supplementary protection certificates, the same to be held and enjoyed by said ASSIGNEE to the full ends of the terms for which said patents, utility models, registrations, confirmations, importation certificates, reexamination certificates, supplementary protection certificates, reissues, renewals and extensions may be granted, as fully and entirely as the same would have been held and enjoyed by SPINIFEX PHARMACEUTICALS PTY LTD if this sale, assignment and transfer had not been made.

SPINIFEX PHARMACEUTICALS PTY LTD hereby authorizes ASSIGNEE and their representatives to insert in paragraph (1) of this Assignment the filing date(s) and Application Number(s) of said patent, utility model, or other application(s) when notified thereof.

SPINIFEX PHARMACEUTICALS PTY LTD hereby covenants and agrees that it will, at any time, (i) upon the request, but at the expense, of ASSIGNEE, execute and deliver all documents that may be necessary or desirable to perfect the title to the foregoing inventions and discoveries, applications, patents, utility models, registrations, confirmations, importation certificates, reissues, renewals, extensions, reexamination certificates, supplementary protection certificates, and applications within the scope of (7) and (8), in ASSIGNEE, including the execution and procurement of all further documents evidencing this sale, assignment and transfer as may be necessary or desirable for recording the same in the patent office or other intellectual property office, agency or the like of any country or region, (ii) upon the request, but at the expense, of ASSIGNEE execute all additional applications within the scope of paragraphs (1) through (6) and all applications within the scope of (7) or (8), and (iii) make all rightful oaths and declarations and do all lawful acts requisite for procuring the same or for aiding therein, without further compensation, but at the expense of ASSIGNEE.

Should any provision of this Assignment be deemed invalid or unenforceable by reason of any law, statute, regulation or judgment, existing now or in the future in any jurisdiction, such provision shall be modified in such jurisdiction so as to nearly approximate the intent of the Parties. If this cannot be done, such invalid or unenforceable provision shall be divisible and be

deleted in any such jurisdiction, and all other provisions shall remain in full force and effect. The modification or deletion of any provision in one jurisdiction shall have no effect on this Assignment in any other jurisdiction.

This Assignment shall be governed by the laws of Switzerland.

This Assignment is effective as from the earliest priority date as stated in attached Schedule of Applications.

Executed this 2 day of November 2015.

SPINFEX PHARMACEUTICALS PTY LTD

BY [Signature] L.S.
Jim Lynch - Authorized Signatory

BY [Signature] L.S.
Kelly Strickerberger, authorized signatory

Witness: [Signature]
Print Name: MAUREEN M'GEE

Witness: [Signature]
Print Name: Lauren Boho

Executed this 2 day of NOVEMBER 2015

NOVARTIS AG

BY [Signature] L.S.
Print Name: Denise Cooper, Authorized Signatory

BY [Signature] L.S.
Print Name: Diane Leone, Authorized Signatory

[Signature]
Witness:
Print Name: MARIA STACHURA

[Signature]
Witness:
Print Name: MARIA FIRA

SCHEDULE A

U.S. Applications

Case reference	Country	Filing Date	Filing Number	Publication Num	Publication Date	Grant Date	Grant Number
PAT057016-US-CNT	United States of America	24 Jun 2011	13/167980	2012-0004259	05 Jan 2012	26 Mar 2013	8404686
PAT057016-US-CNT02	United States of America	28 Mar 2014	14/229746	2014-0228362	14 Aug 2014	28 Apr 2015	9018207
PAT057016-US-DIV	United States of America	03 Aug 2010	12/849727	2011-0318329	29 Dec 2011	23 Jul 2013	8492382
PAT057016-US-DIV02	United States of America	20 Jun 2013	13/923085	2013-0296350	07 Nov 2013	13 May 2014	87222675
PAT057016-US-NP	United States of America	23 Dec 2005	11/315354	2006-0223741	05 Oct 2006	14 Sep 2010	7795275
PAT057017-US-PCT	United States of America	20 Mar 2007	12/294035			08 Oct 2013	8551950
PAT057017-US-PCTD	United States of America	03 Sep 2013	14/016900	2014-0142116	22 May 2014		
PAT057019-US-CNT02	United States of America	20 Sep 2015	14/859347				
PAT057019-US-DIV	United States of America	18 Nov 2013	14/083391	2014-0080865	20 Mar 2014	06 Jan 2015	8927575
PAT057019-US-DIV02	United States of America	17 Dec 2014	14/573774	2015-0105422	16 Apr 2015	20 Oct 2015	9162985
PAT057019-US-NP	United States of America	21 Jul 2011	13/187882	2012-0022101	26 Jan 2012	24 Dec 2013	8614227
PAT057020-US-PCT	United States of America	04 Jan 2013	14/370737	2014-0378430	25 Dec 2014		
PAT057021-US-PCT	United States of America	25 Jan 2013	14/373357	2015-0218180	06 Aug 2015		
PAT057022-US-PCT	United States of America	25 Jan 2013	14/373355	2015-0011565	08 Jan 2015		

PATENT